Log In
BCIQ
Print this Print this
 

afuresertib (GSK2110183)

  Manage Alerts
Collapse Summary General Information
Company Novartis AG
DescriptionProtein kinase B (AKT; AKT1; PKB; PKBA) inhibitor
Molecular Target Protein kinase B (AKT) (AKT1) (PKB) (PKBA)
Mechanism of ActionAkt inhibitor
Therapeutic Modality 

 Product Details
Disease CategoryStandard IndicationIndication DetailsPartnersMilestonesLatest Stage of DevelopmentRegulatory Designation
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

$17,034.0M

$14,800.0M

$2,234.0M


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone

04/28/2014

$17,034.0M

$14,800.0M

$2,234.0M

Get a free BioCentury trial today